Skip to main content

Articles

Page 3 of 67

  1. Current definitions of migraine that are based mainly on clinical characteristics do not account for other patient’s features such as those related to an impaired quality of life, due to loss of social life an...

    Authors: Claudio Tana, Bianca Raffaelli, Marcio Nattan Portes Souza, Elena Ruiz de la Torre, Daniel Gams Massi, Najib Kisani, David García-Azorín and Marta Waliszewska-Prosół
    Citation: The Journal of Headache and Pain 2024 25:12

    The Review to this article has been published in The Journal of Headache and Pain 2023 24:167

  2. Migraine and epilepsy are two paroxysmal chronic neurological disorders affecting a high number of individuals and being responsible for a high individual and socioeconomic burden. The link between these disor...

    Authors: Jakob Paungarttner, Martina Quartana, Lucrezia Patti, Barbora Sklenárová, Fatemeh Farham, Inés Hernando Jiménez, M. Gokcen Soylu, Irina Maria Vlad, Semih Tasdelen, Teresa Mateu, Oreste Marsico, Federica Reina, Viktoria Tischler and Christian Lampl
    Citation: The Journal of Headache and Pain 2024 25:11
  3. Current evidence on the safety of calcitonin gene–related peptide antagonists (CGRP-A) in pregnancy for the treatment of both episodic and chronic migraine is scarce and does not yet provide definitive informa...

    Authors: Roberta Noseda, Francesca Bedussi, Claudio Gobbi, Alessandro Ceschi and Chiara Zecca
    Citation: The Journal of Headache and Pain 2024 25:10
  4. Monoclonal antibodies directed against the neuropeptide calcitonin gene-related peptide (CGRP) are effective in the prevention of chronic and frequent episodic migraine. Since the antibodies do not cross the b...

    Authors: Nadine Friedrich, Krisztina Németh, Martin Tanner, Judit Rosta, Ildikó Dobos, Orsolya Oszlács, Gábor Jancsó, Karl Messlinger and Mária Dux
    Citation: The Journal of Headache and Pain 2024 25:9
  5. Spreading depolarization (SD), underlying mechanism of migraine aura and potential activator of pain pathways, is known to elicit transient local silencing cortical activity. Sweeping across the cortex, the el...

    Authors: Tatiana M. Medvedeva, Maria P. Smirnova, Irina V. Pavlova and Lyudmila V. Vinogradova
    Citation: The Journal of Headache and Pain 2024 25:8
  6. Migraine is a debilitating neurological disorder with pain profile, suggesting exaggerated mechanosensation. Mechanosensitive receptors of different families, which specifically respond to various mechanical s...

    Authors: Adriana Della Pietra, Laura Gómez Dabó, Petr Mikulenka, Christian Espinoza-Vinces, Doga Vuralli, Isil Baytekin, Paolo Martelletti and Rashid Giniatullin
    Citation: The Journal of Headache and Pain 2024 25:6
  7. Despite hypothalamus has long being considered to be involved in the pathophysiology of cluster headache, the inconsistencies of previous neuroimaging studies and a limited understanding of the hypothalamic ar...

    Authors: Stefania Ferraro, Anna Nigri, Maria Grazia Bruzzone, Jean Paul Medina Carrion, Davide Fedeli, Greta Demichelis, Luisa Chiapparini, Giuseppe Ciullo, Ariosky Areces Gonzalez, Alberto Proietti Cecchini, Luca Giani, Benjamin Becker and Massimo Leone
    Citation: The Journal of Headache and Pain 2024 25:7
  8. Given the findings of central effects of erenumab in the literature, we aimed to conduct a rigorous placebo-controlled, double-blind, randomized study to elucidate whether the observed changes are directly att...

    Authors: Hauke Basedau, Kuan-Po Peng, Marlene Schellong and Arne May
    Citation: The Journal of Headache and Pain 2024 25:5
  9. Neuroinflammation, mediated by the activation of microglia, contributes to central sensitization, which is associated with the development of chronic migraine (CM). TREM1 receptors amplify the inflammatory res...

    Authors: Songtang Sun, Zhenzhen Fan, Xuejiao Liu, Longde Wang and Zhaoming Ge
    Citation: The Journal of Headache and Pain 2024 25:3
  10. The pathogenesis of pediatric migraine remains unclear and presents challenges in diagnosis. Recently, growing evidence has indicated that the gut microbiota can exert modulatory functions at the gut-brain axi...

    Authors: Junhui Liu, Kaiyan Xi, Linlin Zhang, Mugu Han, Qingran Wang and Xinjie Liu
    Citation: The Journal of Headache and Pain 2024 25:2
  11. Prior MRI studies on vestibular migraine (VM) have revealed abnormalities in static regional intrinsic brain activity (iBA) and dynamic functional connectivity between brain regions or networks. However, the t...

    Authors: Xing Xiong, Lingling Dai, Wen Chen, Jiajie Lu, Chunhong Hu, Hongru Zhao and Jun Ke
    Citation: The Journal of Headache and Pain 2024 25:1
  12. The World Health Organization (WHO) Intersectoral Global Action Plan on Epilepsy and Other Neurological Disorders was developed by WHO to address the worldwide challenges and gaps in provision of care and serv...

    Authors: Matilde Leonardi, Paolo Martelletti, Rami Burstein, Arianna Fornari, Licia Grazzi, Alla Guekht, Richard B. Lipton, Dimos Dimitrios Mitsikostas, Jes Olesen, Mayowa Ojo Owolabi, Elena Ruiz De la Torre, Simona Sacco, Timothy J. Steiner, Nirmal Surya, Takao Takeshima, Cristina Tassorelli…
    Citation: The Journal of Headache and Pain 2024 25:4
  13. Half of the sufferers of reversible cerebral vasoconstriction syndrome (RCVS) exhibit imaging-proven blood-brain barrier disruption. The pathogenesis of blood-brain barrier disruption in RCVS remains unclear a...

    Authors: Yu-Hsiang Ling, Nai-Fang Chi, Li-Ling Hope Pan, Yen-Feng Wang, Chia-Hung Wu, Jiing-Feng Lirng, Jong-Ling Fuh, Shuu-Jiun Wang and Shih-Pin Chen
    Citation: The Journal of Headache and Pain 2023 24:170
  14. Previous studies have developed the Migraine Aura Complexity Score (MACS) system. MACS shows great potential in studying the complexity of migraine with aura (MwA) pathophysiology especially when implemented i...

    Authors: Katarina Mitrović, Andrej M. Savić, Aleksandra Radojičić, Marko Daković and Igor Petrušić
    Citation: The Journal of Headache and Pain 2023 24:169
  15. Headache disorders are a global public health concern affecting diverse populations. This review examines headache service organizations in low-, middle-, and high-income countries. It addresses global challen...

    Authors: Bianca Raffaelli, Eloísa Rubio-Beltrán, Soo-Jin Cho, Roberto De Icco, Alejandro Labastida-Ramirez, Dilara Onan, Raffaele Ornello, Ruth Ruscheweyh, Marta Waliszewska-Prosół, Roberta Messina and Francesca Puledda
    Citation: The Journal of Headache and Pain 2023 24:167

    The Review to this article has been published in The Journal of Headache and Pain 2024 25:12

  16. To identify primary factors contributing to hemodialysis-related headache (HRH) in maintenance hemodialysis (MHD) patients.

    Authors: Yuqin Xiong, Nujia You, Ruoxi Liao, Ling Wu, Yao Liu, Ziying Ling and Yang Yu
    Citation: The Journal of Headache and Pain 2023 24:166
  17. Migraine is a disabling neurological disorder, characterized by recurrent headaches. During migraine attacks, individuals often experience sensory symptoms such as cutaneous allodynia which indicates the prese...

    Authors: Jérémy Signoret-Genest, Maxime Barnet, François Gabrielli, Youssef Aissouni, Alain Artola, Radhouane Dallel, Myriam Antri, Philip Tovote and Lénaïc Monconduit
    Citation: The Journal of Headache and Pain 2023 24:165
  18. Chronic migraine can be a profoundly disabling disorder that may be treated with preventive medications. However, uncertainty remains as to which preventive medication is the most effective. We present a netwo...

    Authors: Seyran Naghdi, Martin Underwood, Jason Madan, Anna Brown, Callum Duncan, Manjit Matharu, Aiva Aksentyte, Natasha Davies, Sophie Rees, Andrew Cooklin, Amy Grove and Hema Mistry
    Citation: The Journal of Headache and Pain 2023 24:164
  19. The brain functional network topology in new daily persistent headache (NDPH) is not well understood. In this study, we aim to assess the cortical functional network topological characteristics of NDPH using n...

    Authors: Dong Qiu, Zhaoli Ge, Yanliang Mei, Wei Wang, Zhonghua Xiong, Xiaoshuang Li, Ziyu Yuan, Peng Zhang, Mantian Zhang, Xin Liu, Yaqing Zhang, Xueying Yu, Hefei Tang and Yonggang Wang
    Citation: The Journal of Headache and Pain 2023 24:161
  20. In this editorial we aim to provide potential therapeutic options in patients who do not benefit from treatment with CGRP(r) monoclonal antibodies. Based on current real-life studies and analysis of practical ...

    Authors: Marta Waliszewska-Prosół, Doga Vuralli and Paolo Martelletti
    Citation: The Journal of Headache and Pain 2023 24:163
  21. Migraine is the world’s second most common disabling disorder, affecting 15% of UK adults and costing the UK over £1.5 billion per year. Several costly new drugs have been approved by National Institute for He...

    Authors: Hema Mistry, Seyran Naghdi, Martin Underwood, Callum Duncan, Jason Madan and Manjit Matharu
    Citation: The Journal of Headache and Pain 2023 24:162
  22. Cutaneous allodynia is highly prevalent among migraineurs and is associated with a poor prognosis. The Allodynia Symptom Checklist (ASC-12) is a comprehensive questionnaire to identify the presence and severit...

    Authors: Tetiana Marusich, Tibor M Szikszay, Anne Sennholz, Kerstin Luedtke and Gabriela F. Carvalho
    Citation: The Journal of Headache and Pain 2023 24:160
  23. Primary headache disorder is a known risk factor for stroke in women and usually improves during the first trimester of pregnancy. However, despite this, some women develop headaches during pregnancy (G-HA), a...

    Authors: Ki-Woong Nam, Sungyeon Ha, Min-Jeong Oh, Kyungmi Oh, Chi Kyung Kim, Geum Joon Cho, Young Seo Kim and Cheryl D. Bushnell
    Citation: The Journal of Headache and Pain 2023 24:159
  24. Migraine is a primary headache, which has been producing heavy disease burden globally. There is no data on the incidence of migraine among women of childbearing age worldwide, including China. This study aime...

    Authors: Zhuanzhuan Fan, Jian Kang, Wenting Li, Zhiyong Wang, Huifen Qiao and Fei Xu
    Citation: The Journal of Headache and Pain 2023 24:158
  25. Galcanezumab has shown efficacy and effectiveness in the treatment of episodic and chronic migraine (CM), however, the population represented in randomized clinical trials (RCTs) differs from the population ob...

    Authors: Victor Obach, Fernando Velasco, Rocio Alvarez Escudero, María Martín Bujanda, Sonsoles Aranceta, Neus Fabregat, Teresa Marco, Aintzine Ruisanchez, Natalia Roncero, Ane Mínguez-Olaondo, Marta Ruibal, Daniel Guisado-Alonso, Antia Moreira, Elisa Cuadrado-Godia, Amaya Echeverria, Izaro Kortazar Zubizarreta…
    Citation: The Journal of Headache and Pain 2023 24:157
  26. Authors: Xin-yu Li, Cheng-hao Yang, Jia-jie Lv, Hui Liu, Lu-yu Zhang, Min-yi Yin, Zhi-lin Guo and Ru-hong Zhang
    Citation: The Journal of Headache and Pain 2023 24:156

    The original article was published in The Journal of Headache and Pain 2023 24:126

  27. Eptinezumab demonstrated efficacy in adults with migraine and prior preventive treatment failures in the placebo-controlled phase of the DELIVER clinical trial; its long-term effectiveness in this population h...

    Authors: Messoud Ashina, Stewart J. Tepper, Astrid Gendolla, Bjørn Sperling, Anders Ettrup, Mette Krog Josiassen and Amaal J. Starling
    Citation: The Journal of Headache and Pain 2023 24:155
  28. Women are disproportionately affected by migraine, representing up to 75% of all migraine cases. This discrepancy has been proposed to be influenced by differences in hormone levels between the sexes. One such...

    Authors: Aida Maddahi, Karin Warfvinge, Anja Holm, Jacob C. A. Edvinsson, Philip Victor Reducha, Spyridoula Kazantzi, Kristian A. Haanes and Lars Edvinsson
    Citation: The Journal of Headache and Pain 2023 24:154
  29. New acute and preventive migraine medications are available, but data on current treatment patterns are limited. This study describes migraine treatment patterns among patients initiating novel acute migraine ...

    Authors: Zifan Zhou, Robert Urman, Karminder Gill, Andrew S. Park, Fiston Vuvu, Leah B. Patel, Jingsong Lu, Rolin L. Wade, Lindsay Frerichs and Mark E. Bensink
    Citation: The Journal of Headache and Pain 2023 24:153
  30. Randomized clinical trials have demonstrated efficacy and safety of erenumab. The aim of this study is to evaluate the effectiveness and safety of erenumab in a real-world setting in French patients with migra...

    Authors: M. Lanteri-Minet, R. Fabre, C. Martin, K. Pradat, A. Alchaar, E. Bozzolo, M. L. Duchene, E. K. Van Obberghen, A. Donnet and D. Fontaine
    Citation: The Journal of Headache and Pain 2023 24:152
  31. Individuals with migraine frequently experience pre- and post-headache symptoms. This analysis aimed to characterize the relative frequency and burden of pre- and post-headache symptoms in people with migraine...

    Authors: Richard B. Lipton, Michel Lanteri-Minet, Elizabeth Leroux, Aubrey Manack Adams, Janette Contreras-De Lama, Michael L. Reed, Kristina M. Fanning and Dawn C. Buse
    Citation: The Journal of Headache and Pain 2023 24:151
  32. Medication overuse headache (MOH) is a secondary headache that accompanies chronic migraine. Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most frequently used analgesics worldwide and they are known t...

    Authors: Hale Gök Dağıdır, Elif Topa, Doga Vuralli and Hayrunnisa Bolay
    Citation: The Journal of Headache and Pain 2023 24:150
  33. Serum neurofilament light chain (sNfL) can reflect nerve damage. Whether migraine can cause neurological damage remain unclear. This study assesses sNfL levels in migraine patients and explores whether there i...

    Authors: Jie Fang, Jielong Wu, Tengkun Zhang, Xiaodong Yuan, Jiedong Zhao, Liangcheng Zheng, Ganji Hong, Lu Yu, Qing Lin, Xingkai An, Chuya Jing, Qiuhong Zhang, Chen Wang, Zhanxiang Wang and Qilin Ma
    Citation: The Journal of Headache and Pain 2023 24:149
  34. Migraine is a common disabling neurological disorder with severe physical and psychological damage, but there is a lack of convenient and effective non-invasive early prediction methods. This study aimed to de...

    Authors: Shaojie Duan, Hui Xia, Tao Zheng, Guanglu Li, Zhiying Ren, Wenyan Ding, Ziyao Wang and Zunjing Liu
    Citation: The Journal of Headache and Pain 2023 24:148
  35. Preliminary evidence suggests that several headache disorders may be associated with glymphatic dysfunction. However, no studies have been conducted to examine the glymphatic activity in migraine chronification.

    Authors: Xue Zhang, Wei Wang, Xiaoyan Bai, Xueyan Zhang, Ziyu Yuan, Bingjie Jiao, Yingkui Zhang, Zhiye Li, Peng Zhang, Hefei Tang, Yaqing Zhang, Xueying Yu, Ruiliang Bai, Yonggang Wang and Binbin Sui
    Citation: The Journal of Headache and Pain 2023 24:147
  36. Migraine is a brain disorder with recurrent headache attacks and altered sensory processing. Introvision is a self-regulation method based on mindfulness-like perception techniques, developed at the University...

    Authors: Monika Empl, Sonja Löser, Petra Spille, Agnieszka Rozwadowska, Ruth Ruscheweyh and Andreas Straube
    Citation: The Journal of Headache and Pain 2023 24:146
  37. The present study aimed to compare sex differences in the clinical manifestations related to dependence behaviors in medication-overuse headache (MOH).

    Authors: Yen-Feng Wang, Yi-Shiang Tzeng, Chia-Chun Yu, Yu-Hsiang Ling, Shih-Pin Chen, Kuan-Lin Lai, Wei-Ta Chen and Shuu-Jiun Wang
    Citation: The Journal of Headache and Pain 2023 24:145
  38. Monoclonal antibodies (mAbs) targeting the Calcitonin Gene-Related Peptide (CGRP) pathway are safe and effective treatments for migraine prevention. However, the high cost of these novel therapies has led to r...

    Authors: Ja Bin Hong, Kristin Sophie Lange, Mira Fitzek, Lucas Hendrik Overeem, Paul Triller, Anke Siebert, Uwe Reuter and Bianca Raffaelli
    Citation: The Journal of Headache and Pain 2023 24:144
  39. The 2030 Agenda for Sustainable Development sets out, through 17 Sustainable Development Goals (SDGs), a path for the prosperity of people and the planet. SDG 3 in particular aims to ensure healthy lives and p...

    Authors: Paolo Martelletti, Matilde Leonardi, Messoud Ashina, Rami Burstein, Soo-Jin Cho, Augustina Charway-Felli, David W. Dodick, Raquel Gil-Gouveia, Licia Grazzi, Christian Lampl, Antoinette MaassenVanDenBrink, Mia T. Minen, Dimos Dimitrios Mitsikostas, Jes Olesen, Mayowa Ojo Owolabi, Uwe Reuter…
    Citation: The Journal of Headache and Pain 2023 24:140
  40. BMP7 has been shown to have neuroprotective effects and to alleviate demyelination. However, its role in trigeminal neuralgia (TN) has not been well investigated. The current study aims to determine whether BM...

    Authors: Kai Chen, Xiaojin Wei, Ruixuan Wang, Lin Yang, Dingquan Zou and Yaping Wang
    Citation: The Journal of Headache and Pain 2023 24:143
  41. Chronic primary pain (CPP) is an intractable pain of unknown cause with significant emotional distress and/or dysfunction that is a leading factor of disability globally. The lack of a suitable animal model th...

    Authors: An-Ran Liu, Zhen-Jia Lin, Ming Wei, Yuan Tang, Hui Zhang, Xiang-Ge Peng, Ying Li, Yu-Fan Zheng, Zhi Tan, Li-Jun Zhou and Xia Feng
    Citation: The Journal of Headache and Pain 2023 24:141
  42. To determine specific resting-state network patterns underlying alterations in chronic migraine, we employed oscillatory connectivity and machine learning techniques to distinguish patients with chronic migrai...

    Authors: Fu-Jung Hsiao, Wei-Ta Chen, Yu-Te Wu, Li-Ling Hope Pan, Yen-Feng Wang, Shih-Pin Chen, Kuan-Lin Lai, Gianluca Coppola and Shuu-Jiun Wang
    Citation: The Journal of Headache and Pain 2023 24:139
  43. Amygdala, an essential element of the limbic system, has served as an important structure in pain modulation. There is still a lack of clarity about altered cerebral perfusion of amygdala in migraine. This stu...

    Authors: Xiaoyan Bai, Wei Wang, Xueyan Zhang, Zhangxuan Hu, Xue Zhang, Yingkui Zhang, Hefei Tang, Yaqing Zhang, Xueying Yu, Ziyu Yuan, Peng Zhang, Zhiye Li, Xun Pei, Yonggang Wang and Binbin Sui
    Citation: The Journal of Headache and Pain 2023 24:138
  44. The significance of hyperactive astrocytes in neuropathic pain is crucial. However, the association between medullary astrocytes and trigeminal neuralgia (TN)-related pain processing is unclear. Here, we exami...

    Authors: Elina KC, Jaisan Islam, Hyong Kyu Kim and Young Seok Park
    Citation: The Journal of Headache and Pain 2023 24:137
  45. Cluster headache is a severe and disabling primary headache disorder. Galcanezumab is a monoclonal antibody against calcitonin gene-related peptide and a preventive therapy for episodic cluster headache. Howev...

    Authors: Yooha Hong, Mi-Kyoung Kang, Heui-Soo Moon, Byung-Kun Kim and Soo-Jin Cho
    Citation: The Journal of Headache and Pain 2023 24:136
  46. Triptans are effective for many migraine patients, but some do not experience adequate efficacy and tolerability. The European Headache Federation (EHF) has proposed that patients with lack of efficacy and/or ...

    Authors: Ruth Ruscheweyh, Gudrun Gossrau, Thomas Dresler, Tobias Freilinger, Stefanie Förderreuther, Charly Gaul, Torsten Kraya, Lars Neeb, Victoria Ruschil, Andreas Straube, Jörg Scheidt and Tim Patrick Jürgens
    Citation: The Journal of Headache and Pain 2023 24:135
  47. Topiramate is a repurposed first-line treatment for migraine prophylaxis. The aim of this systematic review and meta-analysis is to critically re-appraise the existing evidence supporting the efficacy and tole...

    Authors: Bianca Raffaelli, David García-Azorín, Deirdre M. Boucherie, Faisal Mohammad Amin, Christina I. Deligianni, Raquel Gil-Gouveia, Sarah Kirsh, Christian Lampl, Simona Sacco, Derya Uluduz, Jan Versijpt, Antoinette MaassenVanDenBrink, Dena Zeraatkar, Margarita Sanchez-del-Rio and Uwe Reuter
    Citation: The Journal of Headache and Pain 2023 24:134